Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX⊙ mesalamine: established versus newly diagnosed disease

Abstract

MMX mesalamine is a once daily (QD), oral formulation of 5-aminosalicylic acid for the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). MMX mesalamine utilizes MMX Multi Matrix System® (Cosmo S.p.A., Milan, Italy) technology to delay and extend delivery of mesalamine (1.2g/tablet) throughout the colon. The induction of clinical and endoscopic remission with this formulation has been demonstrated during two 8-week, phase III trials. Here, we examine the ability of MMX mesalamine to induce mucosal healing in patients with recently diagnosed UC, compared with patients who had a longer duration of disease and a history of clinical relapse. Data from the two 8-w..